Index

Note: Page numbers of article titles are in **boldface** type.

A
Abdominal pain
   pancreatitis in feline diabetics and management of, 311–312
Acromegaly
   feline
      pathogenesis of, 227
      hypersomatotropism and, 320
      long-acting insulins in feline diabetes management and, 262
ACTH stimulation test
   in hyperadrenocorticism diagnosis, 338
Adrenalectomy
   unilateral or bilateral
      in hyperadrenocorticism management, 345–346
Antibiotic(s)
   in pancreatitis management in feline diabetics, 312
Azotemia
   in diabetes mellitus
      diabetic nephropathy due to
         in cats, 359–360
         in humans, 359

B
Biguanides
   in feline diabetics, 410–411
Blood glucose monitoring
   in feline diabetics
      home-based, **283–301**. See also Home blood glucose monitoring, in feline diabetics

C
Cat(s)
   acromegaly in
      pathogenesis of, 227
   continuous glucose monitoring in, **381–406**
   diabetes in. See Diabetes mellitus, feline
diabetic nephropathy in, **351–365**. See also Diabetic nephropathy, feline
diabetic remission in, **245–249**. See also Diabetic remission, feline
hyperadrenocorticism in, **330–346**. See also Hyperadrenocorticism, feline
hypersomatotropism in, **319–330**. See also Hypersomatotropism, feline
incretin system in, 425–426
Cat(s) (continued)
  on Lente insulin
    management of, 267–282. See also Lente insulin, management of cats on
    pancreatitis in
    with diabetes, 303–317. See also Pancreatitis, in feline diabetics
    prevalence of, 303

Chromium
  in feline diabetics, 411–412

Cobalamin supplements
  in pancreatitis management in feline diabetics, 313

Continuous glucose monitoring
  in small animals, 381–406
    continuous glucose monitoring system technology, 392–393
    glucose meter technology, 390–393
    initialization/calibration, 399–401
    interstitial and plasma glucose relationships, 392
    introduction to, 381–382
    laboratory monitoring, 390–391
    patient groups benefiting from, 382–390
      critical care patients, 382–385
        feline, 384–385
        humans, 383–384
      diabetic patients undergoing surgery or anesthesia, 389–390
    long-term monitoring, 385–389
    placement strategies and patient tolerance for, 396–398
    point-of-care monitoring, 391–392
    sensor lifespan/stability, 398–399
    systems for, 392–396

Crystalloid therapy
  in pancreatitis management in feline diabetics, 310

D

DDP-4 inhibitors. See Dipeptidyl-peptidase 4 (DDP-4) inhibitors

Detemir
  dosing protocol for, 252–259
  storage of, 259

Diabetes mellitus
  azotemia in
    diabetic nephropathy due to
      in cats, 359–360
      in humans, 359
    classification of, 351–352
  defined, 221, 367
  dyslipidemia in
    diabetic nephropathy due to
      in cats, 359
      in humans, 358–359
  feline
    control of
      pancreatitis effects on, 309–310
described, 221–223, 425
home blood glucose monitoring in, 283–301. See also Home blood glucose monitoring, in feline diabetics
hypersomatotropism and, 319–330. See also Hypersomatotropism
management of
   DDP-4 in, 413, 417–433
diabetic stabilization in
goals of, 267–268
diet in, 233–243, 269–270. See also Diet, in prevention/management of feline diabetes
   GLP-1 in, 417–433. See also Glucagon-like peptide 1 (GLP-1), in feline diabetes for increasing chance for remission, 246–247
   insulin therapy in. See Insulin(s); Lente insulin
   Lente insulin in, 267–282. See also Lente insulin, management of cats on long-acting insulins in, 251–266. See also Long-acting insulins, in feline diabetes management
oral hypoglycemics in, 407–415. See also specific drugs and Hypoglycemic(s), oral, in feline diabetics
pancreatitis with, 303–317. See also Pancreatitis, in feline diabetics
pathogenesis of, 221–231
decreased insulin secretion in, 224–227
decreased insulin sensitivity in, 224
described, 223–224
pancreatitis-associated diabetes in, 227–228
prevention of
   diet in, 233–243. See also Diet, in prevention/management of feline diabetes
relapse of
   long-acting insulins and, 263–264
remission in, 245–249. See also Diabetic remission, feline
   Lente insulin and, 276–277
hypertension in
diabetic nephropathy due to
   in cats, 357–358
   in humans, 356–357
pancreatitis-associated
feline
   pathogenesis of, 227–228
proteinuria in
diabetic nephropathy due to
   in cats, 361–362
   in humans, 361
type 2
   in humans
      GLP-1 and GIP in, 419, 421
      incretin-based therapies for, 421–424
Diabetic ketoacidosis (DKA)
feline, 367–379
   assessment of, 368–370
   clinical signs of, 368–370
   concurrent diseases with
testing for, 370–371
Diabetic (continued)
  described, 367–368
  diagnosis of, 368–370
  treatment of, 371–377
    fluid and electrolytes in, 371–374
    insulin in, 374–377
Diabetic nephropathy
  causes of, 355–362
    azotemia in diabetes mellitus
      in cats, 359–360
      in humans, 359
    dyslipidemia in diabetes mellitus
      in cats, 359
      in humans, 358–359
    genetic, 355
    hyperglycemia, 355–356
    proteinuria in diabetes mellitus
      in cats, 361–362
      in humans, 361
  clinical consequences of, 359–362
feline, 351–365
  causes of, 359–362
  histopathology of, 353
  incidence of, 352
in humans
  causes of, 358–359, 361
  histopathology of, 352
  incidence of, 352
  terminology related to, 352
promoters of, 356–359
  hypertension in diabetes mellitus, 356–358
stages of, 354–355
  terminology related to, 352
Diabetic remission
feline, 245–249
  defined, 245
  factors associated with, 247–248
    increasing chance for diabetes management in, 246–247
    pathophysiology of, 245–246
    relapse from, 248
  long-acting insulins effects on, 263–264
DIC. See Disseminated intravascular coagulation (DIC)
Diet
  low-carbohydrate
    in feline diabetes management, 260
    in prevention/management of feline diabetes, 233–243, 269–270
      background of, 233–234
      role of, 234–240
Dipeptidyl-peptidase 4 (DDP-4) inhibitors
  described, 417
for diabetes
  in cats, 413, **417–433**
  in humans, 423–424
Disseminated intravascular coagulation (DIC)
  pancreatitis in feline diabetics and
  prevention/management of, 312
DKA. See Diabetic ketoacidosis (DKA)
Dopamine
  in pancreatitis management in feline diabetics, 312–313
Dyslipidemia
  in diabetes mellitus
    diabetic nephropathy due to
      in cats, 359
      in humans, 358–359

E
Endocrine testing
  in hyperadrenocorticism, 336–339
    ACTH stimulation test, 338
    LDDST, 336–338
    UCCR, 338
  in hypersomatotropism, 326–328

F
Fluid and electrolytes
  abnormalities of
    pancreatitis in feline diabetics and, 310–311
    in DKA management, 371–374
Fructosamine
  in feline diabetes management, 260

G
Gastric inhibitory polypeptide (GIP)
  in feline diabetes
    biological actions of, 419, 420
    biosynthesis of, 418–419
    described, 419
    metabolism of, 418–419
    secretion of, 418–419
  in humans with type 2 diabetes mellitus, 419, 421
Genetic(s)
  diabetic nephropathy due to, 355
GIP. See Gastric inhibitory polypeptide (GIP)
Glargine
  dosing protocol on
    in feline diabetes management, 252–259
    storage of, 259
GLP-1. See Glucagon-like peptide 1 (GLP-1)
Glucagon-like peptide 1 (GLP-1)
in feline diabetes, 417–433
  biological actions of, 419, 420
  biosynthesis of, 418–419
  described, 417–418
  metabolism of, 418–419
  secretion of, 418–419
  in humans with type 2 diabetes mellitus, 419, 421
Glucagon-like peptide 1 (GLP-1) receptor agonists
  for diabetes
    in cats, 426–427
    in humans, 421–423
Glucocorticoid(s)
in pancreatitis management in feline diabetics, 313
Glucometer(s)
  veterinary vs. human
    in home blood glucose monitoring in feline diabetics, 287–288
Glucose meter technology, 390–393
Glucose monitoring
  continuous
    in small animals, 381–406. See also Continuous glucose monitoring, in small animals
  home-based
    in feline diabetes, 283–301. See also Home blood glucose monitoring, in feline diabetics
α-Glucosidase inhibitors
  in feline diabetics, 412–413

H
Home blood glucose monitoring
  in feline diabetics, 283–301
    collection sites, 288–290
      lateral ear margin, 288–289
      pisiform paw pad, 290
    communication with cat owners, 292–293
    described, 287
    insulin dosage chart, 295–297
    introduction to, 283–284
    lancing devices, 290–291
    long-term evaluation and follow-up, 297–300
    as new standard of care, 284–285
    reasons for, 285–286
    as routine, 287
    strategies for, 293–297
      daily/multiple times per day monitoring, 294–295
      home blood glucose curves, 293–294
      spot check blood glucose reading, 293
      veterinary-directed insulin prescription, 295–297
      veterinary vs. human glucometers, 287–288
      working with pet owner, 291–292
Hyperadrenocorticism
  feline, 330–346
    causes of, 332–333
    described, 330–331
    diagnosis of, 334–339
      endocrine testing in, 336–339
      plasma ACTH precursors in, 339
      routine clinical pathology in, 334–335
    hypoadrenocorticism vs., 346
    imaging of, 339–343
    presentation of, 333–334
    prevalence of, 331–332
    quality of life with, 346–347
    signalment of, 333–334
    treatment of, 343–346
      medical, 343–345
      palliative, 346
      radiation therapy in, 346
      surgical, 345–346
Hyperglycemia
  diabetic nephropathy due to, 355–356
  insulin-induced rebound
    long-acting insulins in feline diabetes management and, 262
Hyperosmolar syndrome
  feline, 367–379
    assessment of, 368–370
    clinical signs of, 368–370
    described, 367–368
    diagnosis of, 368–370
    treatment of, 371–377
      fluid and electrolytes in, 371–374
      insulin in, 374–377
Hypersomatotropism
  feline, 319–330
    acromegaly and, 320
    causes of, 322
    diagnosis of, 325–328
      endocrine testing in, 326–328
      routine clinical pathology in, 325–326
    hyperadrenocorticism vs., 346
    imaging in, 328
    pathogenesis of, 227
    presentation of, 322–325
    prevalence of, 320–322
    quality of life with, 346–347
    signalment of, 322–325
    treatment of, 328–330
      medical, 328–329
      palliative, 330
      radiation therapy in, 330
Hyperadrenocorticism (continued)
- surgical, 329–330
Hypertension
- in diabetes mellitus
  - diabetic nephropathy due to, 356–357
  - in cats, 357–358
  - in humans, 356–357
Hyperthyroidism
- long-acting insulins in feline diabetes management and, 262
Hypoglycemia
- long-acting insulins in feline diabetes management and, 260–261
Hypoglycemic(s)
  - oral
    - in feline diabetics, 407–415. See also specific drugs
      - biguanides, 410–411
      - chromium, 411–412
      - DDP-4 inhibitors, 413
      - $\alpha$-glucosidase inhibitors, 412–413
      - meglitinides, 410
      - sulfonylurea drugs, 408–410
      - thiazolidinediones, 411
      - tungsten, 412
      - vanadium, 412
Hypophysectomy
- in hyperadrenocorticism management, 345

I
Incretin-based therapies
- for diabetes
  - in cats
    - DDP-4 inhibitors, 427–428
    - described, 425–426
    - GLP-1 receptor agonists, 426–427
  - in humans, 421–424
    - DDP-4 inhibitors, 423–424
    - GLP-1 receptor agonists, 421–423
Insulin(s)
- in DKA management, 374–377
- in feline diabetes management, 270–271. See also specific types
  - long-acting
    - in feline diabetes management, 251–266. See also Long-acting insulins, in feline diabetes management
Insulin-induced rebound hyperglycemia
- long-acting insulins in feline diabetes management and, 262
Insulin resistance
- long-acting insulins in feline diabetes management and, 262
Insulin secretion
- decreased
  - in pathogenesis of feline diabetes, 224–227
Insulin sensitivity
decreased
  in pathogenesis of feline diabetes, 224

K
Ketoacidosis
diabetic
  feline, 367–379. See also Diabetic ketoacidosis (DKA), feline
  long-acting insulins in feline diabetes management and, 261
Kidney(s)
in humans and in veterinary medicine, 351–365. See also Diabetic nephropathy

L
LDDST
  in hyperadrenocorticism diagnosis, 336–338
Lente insulin
  management of cats on, 267–282
    blood glucose curves with, 274–276
    complex case management, 277–278
    described, 270–271
    diabetes monitoring with, 271–273
    dose adjustments, 276
    introduction to, 267–269
    long-term care with, 277
    remission with, 276–277
    resistance to, 278–279
Long-acting insulins
  in feline diabetes management, 251–266
    aims of therapy with, 251
    complications of, 260–262
      acromegaly, 262
      hyperthyroidism, 262
      hypoglycemia, 260–261
      insulin resistance, 262
      ketoacidosis, 261
      Somogyi effect, 262
    dosage adjustment protocols, 252–260
      fructosamine, 260
      glargine/detemir, 252–259
      urine testing, 260
    low-carbohydrate diet with, 260
    relapse related to, 263–264
    remission rates related to, 263–264
    types of, 252
Low-carbohydrate diet
  in feline diabetes management, 260

M
Meglitinides
  in feline diabetics, 410
Nephropathy
diabetic
  feline, 351–365. See also Diabetic nephropathy, feline
Nutrition
  in pancreatitis management in feline diabetics, 311

O
Oral pancreatic enzyme supplements
  in pancreatitis management in feline diabetics, 312

P
Pain
  abdominal
    pancreatitis in cats with diabetes and
    management of, 311–312
Pancreatic enzyme supplements
  oral
    in pancreatitis management in feline diabetics, 312
Pancreatitis
  in cats
    prevalence of, 303
  in feline diabetics, 303–317
    clinical signs of, 306
    diagnosis of, 306–309
    impact on assessment, 309
    impact on control, 309–310
    introduction to, 303–305
    management of, 310–313
      abdominal pain–related, 311–312
      antibiotics in, 312
      cobalamin supplements in, 313
      crystalloid therapy in, 310
      DIC-related, 312
      dopamine in, 312–313
      glucocorticoids in, 313
      nutrition in, 311
      oral pancreatic enzyme supplements in, 312
      plasma transfusions in, 310–311
      surgical, 313
      ursodeoxycholic acid in, 313
      vomiting-related, 312
    prevalence of, 305–306
Pancreatitis-associated diabetes mellitus
  feline
    pathogenesis of, 227–228
Plasma ACTH precursors
  in hyperadrenocorticism diagnosis, 339
Index

Plasma transfusions
  in pancreatitis management in feline diabetics, 310–311
Proteinuria
  in diabetes mellitus
    diabetic nephropathy due to
      in cats, 361–362
      in humans, 361

R
Radiation therapy
  in hyperadrenocorticism management, 346
  in hypersomatotropism management, 330

S
Small animals
  continuous glucose monitoring in, 381–406. See also Continuous glucose monitoring, in small animals
Somogyi effect
  long-acting insulins in feline diabetes management and, 262
Sulfonylurea drugs
  in feline diabetics, 408–410

T
Thiazolidinediones
  in feline diabetics, 411
Transfusion(s)
  plasma
    in pancreatitis management in feline diabetics, 310–311
Tungsten
  in feline diabetics, 412

U
UCCR
  in hyperadrenocorticism diagnosis, 338
Ursodeoxycholic acid
  in pancreatitis management in feline diabetics, 313

V
Vanadium
  in feline diabetics, 412
Vomiting
  pancreatitis in feline diabetics and management of, 312